Positive News Sentiment NASDAQ:OCUL Ocular Therapeutix Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.09 +0.07 (+1.74%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$3.95▼$4.2050-Day Range$3.01▼$4.2152-Week Range$2.91▼$14.49Volume472,611 shsAverage Volume645,862 shsMarket Capitalization$313.95 millionP/E RatioN/ADividend YieldN/APrice Target$17.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ocular Therapeutix Stock Forecast (MarketRank)Analyst RatingBuy3.25 Rating ScoreUpside/Downside334.0% Upside$17.75 Price TargetShort InterestHealthy4.61% of Float Sold ShortDividend StrengthN/ASustainability-2.01Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.81) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.17 out of 5 starsMedical Sector402nd out of 1,428 stocksPharmaceutical Preparations Industry187th out of 682 stocks 3.6 Analyst's Opinion Consensus RatingOcular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.75, Ocular Therapeutix has a forecasted upside of 334.0% from its current price of $4.09.Amount of Analyst CoverageOcular Therapeutix has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.61% of the float of Ocular Therapeutix has been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Ocular Therapeutix has recently decreased by 11.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOcular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ocular Therapeutix is -2.01. Previous Next 2.7 News and Social Media Coverage News SentimentOcular Therapeutix has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Ocular Therapeutix this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions53.94% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ocular Therapeutix are expected to grow in the coming year, from ($0.81) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address About Ocular Therapeutix (NASDAQ:OCUL)Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Read More OCUL Stock News HeadlinesJune 16, 2022 | marketwatch.comLacrimal Devices Market Size 2022 by Product, Revenue, Price, Industry Share, Growth Opportunity and Forecast to 2028June 13, 2022 | finance.yahoo.comIs Ocular Therapeutix (NASDAQ:OCUL) A Risky Investment?June 8, 2022 | finance.yahoo.comOcular Therapeutix™ Announces Organizational Changes to Support Development for Retinal DiseasesMay 13, 2022 | finance.yahoo.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Just Slashed This Year's Revenue Estimates By 20%May 9, 2022 | ph.investing.comOcular Therapeutix Tops Q1 EPS by 4cMay 9, 2022 | finance.yahoo.comOcular Therapeutix™ Reports First Quarter 2022 Financial Results and Business UpdateMay 2, 2022 | benzinga.comOphthalmic Drug Delivery Systems Market Revenue to Surpass US$ 24,556 Mn By 2030 – Exclusive Report By Acumen Research And ConsultingApril 26, 2022 | finance.yahoo.comOcular Therapeutix™ to Report First Quarter 2022 Financial ResultsApril 25, 2022 | finance.yahoo.comOcular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingApril 22, 2022 | morningstar.comVerana Health Unveils Annual Ophthalmic Industry Report that Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year PeriodApril 18, 2022 | marketwatch.comOcular Drug Delivery System Market Size 2022–Global Industry Analysis, Trends, Market Demand, Growth, Opportunities and Forecast 2028April 14, 2022 | finance.yahoo.comOcular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingApril 12, 2022 | markets.businessinsider.comAffaMed : Dextenza Approved In Macau For Treatment Of Ocular Inflammation After Ophthalmic SurgeryApril 12, 2022 | finance.yahoo.comAffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic SurgeryMarch 17, 2022 | finance.yahoo.comAdverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of DirectorsMarch 2, 2022 | finance.yahoo.comTime To Worry? Analysts Are Downgrading Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) OutlookMarch 1, 2022 | benzinga.comJMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $22February 28, 2022 | benzinga.comRecap: Ocular Therapeutix Q4 EarningsFebruary 27, 2022 | seekingalpha.comOcular Therapeutix Q4 2021 Earnings PreviewFebruary 22, 2022 | finance.yahoo.comOcular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial ResultsFebruary 11, 2022 | finance.yahoo.comOcular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360February 2, 2022 | nz.finance.yahoo.comWorldwide Hydrogel-based Drug System Industry to 2027 - Therapeutic Values of the Hydrogel-based Drug Delivery System are Driving GrowthJanuary 26, 2022 | nasdaq.comOcular Therapeutix, Inc. Common Stock (OCUL)January 25, 2022 | ca.finance.yahoo.comGlobal Hydrogel-based Drug System Market (2021 to 2027) - Featuring Medtronic, Galderma and Endo International Among Others - ResearchAndMarkets.comJanuary 19, 2022 | seekingalpha.comOcular Therapeutix owner buys 50,000 shares worth ~$300KSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCUL CUSIPN/A CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees228Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today7/02/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$17.75 High Stock Price Forecast$29.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+334.0%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.930010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6.55 million Net Margins-45.00% Pretax Margin-45.00% Return on Equity-26.50% Return on Assets-10.57% Debt Debt-to-Equity Ratio0.65 Current Ratio7.29 Quick Ratio7.23 Sales & Book Value Annual Sales$43.52 million Price / Sales7.21 Cash FlowN/A Price / Cash FlowN/A Book Value$1.15 per share Price / Book3.56Miscellaneous Outstanding Shares76,760,000Free Float73,997,000Market Cap$313.95 million OptionableOptionable Beta1.80 Ocular Therapeutix Frequently Asked Questions Should I buy or sell Ocular Therapeutix stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ocular Therapeutix stock. View analyst ratings for Ocular Therapeutix or view top-rated stocks. What is Ocular Therapeutix's stock price forecast for 2022? 4 brokerages have issued 12 month target prices for Ocular Therapeutix's stock. Their OCUL stock forecasts range from $10.00 to $29.00. On average, they expect Ocular Therapeutix's stock price to reach $17.75 in the next year. This suggests a possible upside of 334.0% from the stock's current price. View analysts' price targets for Ocular Therapeutix or view top-rated stocks among Wall Street analysts. How has Ocular Therapeutix's stock performed in 2022? Ocular Therapeutix's stock was trading at $6.97 on January 1st, 2022. Since then, OCUL shares have decreased by 41.3% and is now trading at $4.09. View the best growth stocks for 2022 here. When is Ocular Therapeutix's next earnings date? Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Ocular Therapeutix. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.03. The biopharmaceutical company had revenue of $13.19 million for the quarter, compared to the consensus estimate of $15.03 million. Ocular Therapeutix had a negative net margin of 45.00% and a negative trailing twelve-month return on equity of 26.50%. View Ocular Therapeutix's earnings history. Who are Ocular Therapeutix's key executives? Ocular Therapeutix's management team includes the following people: Mr. Antony Mattessich, Pres, CEO & Director (Age 55, Pay $1.04M) (LinkedIn Profile)Mr. Donald Notman Jr., Chief Financial OfficerDr. Michael H. Goldstein M.M., M.D., M.B.A., Pres of Ophthalmology & Chief Medical Officer (Age 55, Pay $735.75k)Dr. Peter K. Jarrett Ph.D., Chief Scientific Officer (Age 65)Mr. Philip C. Strassburger, Gen. Counsel (Age 62)Mr. William H. Ransone II, VP of Global Sales & MarketingMs. Tracy Smith, VP of HRMr. Scott Corning, Sr. VP of CommercialMr. Christopher G. White, Chief Bus. Officer (Age 60)Dr. Rabia Gurses Ozden M.D., Sr. VP of Clinical Devel. (Age 53) Who are some of Ocular Therapeutix's key competitors? Some companies that are related to Ocular Therapeutix include Myovant Sciences (MYOV), Kura Oncology (KURA), 23andMe (ME), Amylyx Pharmaceuticals (AMLX), Prometheus Biosciences (RXDX), Arcutis Biotherapeutics (ARQT), Reata Pharmaceuticals (RETA), IVERIC bio (ISEE), Syndax Pharmaceuticals (SNDX), Vectura Group (VEGPF), FibroGen (FGEN), Cassava Sciences (SAVA), Revance Therapeutics (RVNC), Innoviva (INVA) and Enanta Pharmaceuticals (ENTA). View all of OCUL's competitors. What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), (CELG), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX). What is Ocular Therapeutix's stock symbol? Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL." How do I buy shares of Ocular Therapeutix? Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ocular Therapeutix's stock price today? One share of OCUL stock can currently be purchased for approximately $4.09. How much money does Ocular Therapeutix make? Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $313.95 million and generates $43.52 million in revenue each year. The biopharmaceutical company earns $-6.55 million in net income (profit) each year or ($0.930010) on an earnings per share basis. How many employees does Ocular Therapeutix have? Ocular Therapeutix employs 228 workers across the globe. How can I contact Ocular Therapeutix? Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for Ocular Therapeutix is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001. This page (NASDAQ:OCUL) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
